Safety of Thrombolysis in Acute Ischemic Stroke: a Review of Complications, Risk Factors, and Newer Technologies

Overview

Journal Neurohospitalist

Publisher Sage Publications

Date 2013 Aug 29

PMID 23983849

Citations 95

Authors

Daniel J Miller

Jennifer R Simpson

Brian Silver

Affiliations

Soon will be listed here.

Abstract

Intravenous recombinant tissue plasminogen activator (r-tPA) was approved for use in acute ischemic stroke in the United States in 1996. Approximately 2% to 5% of patients with acute ischemic stroke receive r-tPA. Complications related to intravenous r-tPA include symptomatic intracranial hemorrhage, major systemic hemorrhage, and angioedema in approximately 6%, 2%, and 5% of patients, respectively. Risk factors for symptomatic hemorrhage include age, male gender, obesity, increased stroke severity, diabetes, hyperglycemia, uncontrolled hypertension, combination antiplatelet use, large areas of early ischemic change, atrial fibrillation, congestive heart failure, and leukoariosis. A risk factor for angioedema is the use of angiotensin-converting enzyme inhibitor. Risk assessment scores, novel imaging strategies, and telemedicine may offer methods of optimizing the risk-benefit ratio.

Citing Articles

Management of acute ischemic stroke in the emergency department: optimizing the brain.

Ganti L Int J Emerg Med. 2025; 18(1):7.

PMID: 39773368 PMC: 11708089. DOI: 10.1186/s12245-024-00780-5.

Dual role of vascular endothelial growth factor-C in post-stroke recovery.

Choi Y, Hsu M, Laaker C, Port J, Kovacs K, Herbath M J Exp Med. 2024; 222(2).

PMID: 39665829 PMC: 11636551. DOI: 10.1084/jem.20231816.

Large right middle cerebral artery stroke with hemorrhagic transformation.

Niles J, Bhasin G, Ganti L Int J Emerg Med. 2024; 17(1):138.

PMID: 39367308 PMC: 11453048. DOI: 10.1186/s12245-024-00739-6.

Life-Threatening tPA-Associated Angioedema: A Rare Case Report and Critical Review.

El Labban M, El Zibaoui R, Amadi A, Zareen T, Khan S Am J Case Rep. 2024; 25:e944221.

PMID: 39275799 PMC: 11409825. DOI: 10.12659/AJCR.944221.

Ultrasound-responsive theranostic platform for the timely monitoring and efficient thrombolysis in thrombi of tPA resistance.

Lin L, Ba Z, Tian H, Qin H, Chen X, Zhou X Nat Commun. 2024; 15(1):6610.

PMID: 39098904 PMC: 11298549. DOI: 10.1038/s41467-024-50741-y.

References

Derex L, Hermier M, Adeleine P, Pialat J, Wiart M, Berthezene Y . Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry. 2004; 76(1):70-5. PMC: 1739325. DOI: 10.1136/jnnp.2004.038158. View

Kent D, Selker H, Ruthazer R, Bluhmki E, Hacke W . The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 2006; 37(12):2957-62. DOI: 10.1161/01.STR.0000249054.96644.c6. View

Albers G, Bates V, Clark W, Bell R, Verro P, Hamilton S . Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283(9):1145-50. DOI: 10.1001/jama.283.9.1145. View

Longstreth Jr W, Katz R, Tirschwell D, Cushman M, Psaty B . Intravenous tissue plasminogen activator and stroke in the elderly. Am J Emerg Med. 2010; 28(3):359-63. PMC: 2837849. DOI: 10.1016/j.ajem.2009.01.025. View

De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R . Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis. 2010; 30(5):533-4. DOI: 10.1159/000319886. View

Marler J, Tilley B, Lu M, Brott T, Lyden P, Grotta J . Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000; 55(11):1649-55. DOI: 10.1212/wnl.55.11.1649. View

Demchuk A, Khan F, Hill M, Barber P, Silver B, Patel S . Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis. 2008; 26(2):120-5. PMC: 2914449. DOI: 10.1159/000139658. View

Rudolf J, Grond M, Schmulling S, Neveling M, Heiss W . Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology. 2000; 55(4):599-600. DOI: 10.1212/wnl.55.4.599. View

Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N . Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009; 8(12):1095-102. DOI: 10.1016/S1474-4422(09)70264-9. View

10.

Kidwell C, Saver J, Mattiello J, Starkman S, Vinuela F, Duckwiler G . Diffusion-perfusion MRI characterization of post-recanalization hyperperfusion in humans. Neurology. 2001; 57(11):2015-21. DOI: 10.1212/wnl.57.11.2015. View

11.

Dorado L, Millan M, Perez de la Ossa N, Guerrero C, Gomis M, Lopez-Cancio E . Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis. Eur J Neurol. 2009; 17(2):301-6. DOI: 10.1111/j.1468-1331.2009.02843.x. View

12.

Smith W, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind D . Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008; 39(4):1205-12. DOI: 10.1161/STROKEAHA.107.497115. View

13.

Palumbo V, Boulanger J, Hill M, Inzitari D, Buchan A . Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology. 2007; 68(13):1020-4. DOI: 10.1212/01.wnl.0000257817.29883.48. View

14.

Del Zoppo G, Saver J, Jauch E, Adams Jr H . Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40(8):2945-8. PMC: 2782817. DOI: 10.1161/STROKEAHA.109.192535. View

15.

Morgenstern L, Hemphill 3rd J, Anderson C, Becker K, Broderick J, Connolly Jr E . Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41(9):2108-29. PMC: 4462131. DOI: 10.1161/STR.0b013e3181ec611b. View

16.

Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G . Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke. 2005; 36(11):2421-5. DOI: 10.1161/01.STR.0000185696.73938.e0. View

17.

Albers G, Thijs V, Wechsler L, Kemp S, Schlaug G, Skalabrin E . Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006; 60(5):508-517. DOI: 10.1002/ana.20976. View

18.

Dowlatshahi D, Hakim A, Fang J, Sharma M . Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: a cohort from the Registry of the Canadian Stroke Network. Int J Stroke. 2009; 4(5):328-34. DOI: 10.1111/j.1747-4949.2009.00331.x. View

19.

Schellinger P, Bryan R, Caplan L, Detre J, Edelman R, Jaigobin C . Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010; 75(2):177-85. PMC: 2905927. DOI: 10.1212/WNL.0b013e3181e7c9dd. View

20.

Demchuk A, Morgenstern L, Krieger D, Chi T, Hu W, Wein T . Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999; 30(1):34-9. DOI: 10.1161/01.str.30.1.34. View